Dr. Reddy’s Laboratories has sold its antibiotic manufacturing facility and related assets in Bristol, Tennessee to Neopharma, a wholly owned subsidiary of the UAE's largest pharmaceutical manufacturer headquartered in Abu Dhabi. Under the terms of the agreement, the company sold all the issued and outstanding membership interests in Dr. Reddy's Laboratories Tennessee, LLC and certain related assets.
The plant and associated facilities focus on manufacturing or packaging amoxicillin-based products, which include a semi-synthetic penicillin. The 390,000-square-foot facility is dedicated to secondary oral-solid dose penicillin manufacturing/packaging and includes processing, packaging, development, printing, and warehouse spaces. A separate 24,000-square-foot plastics-processing facility in Bristol is also included in the transaction.
Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.
